Get notified when PRAX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPRAX: net income -$92.6M. PRAX advances two NDAs to FDA review, raises in equity to fund commercial launch prep
Filed May 7, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 2, 2025 · ~1 min read
Key Changes
-
high
Submitted NDAs for ulixacaltamide (essential tremor, PDUFA Jan 2027) and relutrigine (SCN2A/SCN8A epilepsy, priority review PDUFA Sep 2026); commercial preparations underway for both programs.
MD&A: NDA submissions verify on EDGAR → -
high
Raised across two follow-on offerings (Oct 2025: Jan 2026: at), tripling cash position and extending runway into 2028.
MD&A: Equity raises verify on EDGAR → -
high
Announced positive topline results from elsunersen EMBRAVE Part A study (SCN2A gain-of-function epilepsy) in April 2026; Phase 3 registrational study EMBRAVE3 enrolling with results expected 2027.
MD&A: Elsunersen program verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (CALM 10-Q) is open in full — no account needed.
Partner
Trade PRAX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 3, 2026 · How we verify